Integrated Filing — IndAS



General information about company

Scrip Code 543748
NSE Symbol AARTIPHARM
MSEI Symbol NOTLISTED
ISIN INE0LRU01027
Name of company Aarti Pharmalabs Ltd
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 28-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 09-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 28-10-2026   14:00:00
End date and time of board meeting 28-10-2026   19:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 16-03-2026
Indicate Company website link for updated RPT policy of the Company https://www.aartipharmalabs.com/investors/apl-amended-rpt-policy-march-2026-final.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 61,258.69 1,14,717.47
Other income 46.55 339.68
Total income 61,305.24 1,15,057.15
2 Expenses
(a) Cost of materials consumed 33,190.52 58,674.61
(b) Purchases of stock-in-trade 2,143.26 4,588.18
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (5,252.96) (9,525.16)
(d) Employee benefit expense 5,394.43 10,370.98
(e) Finance costs 1,495.09 2,782.45
(f) Depreciation, depletion and amortisation expense 3,052.67 6,055.49
(f) Other Expenses
1 Foreign Exchange (Gain)/Loss (53.23) (399.34)
2 Other Expenses 12,204.39 23,756.45
Total other expenses 12,151.16 23,357.11
Total expenses 52,174.17 96,303.66
3 Total profit before exceptional items and tax 9,131.07 18,753.49
4 Exceptional items (204.00) (204.00)
5 Total profit before tax 8,927.07 18,549.49
6 Tax expense
7 Current tax 2,013.00 4,027.00
8 Deferred tax 338.78 816.53
9 Total tax expenses 2,351.78 4,843.53
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,575.29 13,705.96
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 6,575.29 13,705.96
17 Other comprehensive income net of taxes (143.96) 38.19
18 Total Comprehensive Income for the period 6,431.33 13,744.15
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,533.99 4,533.99
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.25 15.12
Diluted earnings (loss) per share from continuing operations 7.24 15.1
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.25 15.12
Diluted earnings (loss) per share from continuing and discontinued operations 7.24 15.1
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,46,590.22
Capital work-in-progress 30,824.48
Investment property
Goodwill 0.00
Other intangible assets 3,457.57
Intangible assets under development 10,391.49
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 4,335.23
Trade receivables, non-current
Loans, non-current 801.24
Other non-current financial assets
1 Other Financial Assets 3,598.87
Total of other non-current financial assets 3,598.87
Total non-current financial assets 8,735.34
Deferred tax assets (net)
Other non-current assets
1 Other Non-Current Assets 859.86
Total of other non-current assets 859.86
Total non-current assets 2,00,858.96
2 Current assets
Inventories 78,824.83
Current financial asset
Current investments 0.00
Trade receivables, current 69,514.65
Cash and cash equivalents 115.80
Bank balance other than cash and cash equivalents 1,907.62
Loans, current 58.58
Other current financial assets
Total of other current financial assets 21.83
Total current financial assets 71,618.48
Current tax assets (net)
Other current assets
1 Other Current Assets 15,329.00
Total of other current assets 15,329.00
Total current assets 1,65,772.31
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3,66,631.27
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,533.99
Other equity 2,05,793.13
Total equity attributable to owners of parent 2,10,327.12
Non controlling interest
Total equity 2,10,327.12
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 15,983.82
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 4,349.99
2 Other Financial Liabilities 3,682.86
Total of other non-current financial liabilities 8,032.85
Total non-current financial liabilities 24,016.67
Provisions, non-current 911.73
Deferred tax liabilities (net) 14,261.84
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 39,190.24
Current liabilities
Current financial liabilities
Borrowings, current 67,663.62
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 58.43
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 35,608.96
Total Trade payable 35,667.39
Other current financial liabilities
1 Lease Liabilities 1,715.13
2 Others Financial Liabilities 7,690.63
Total of other current financial liabilities 9,405.76
Total current financial liabilities 1,12,736.77
Other current liabilities 2,149.96
1 Other Current Liabilities 2,149.96
Total of other current liabilities 2,149.96
Provisions, current 1,901.98
Current tax liabilities (Net) 325.20
Deferred government grants, Current
Total current liabilities 1,17,113.91
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,56,304.15
Total equity and liabilites 3,66,631.27
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 231.72 246.52
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss (87.76) (284.71)
5 Total Other comprehensive income (143.96) 38.19



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 18,549.49
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,782.45
Adjustments for decrease (increase) in inventories (15,203.46)
Adjustments for decrease (increase) in trade receivables, current (13,032.18)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets (81.45)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 6,731.82
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 6,055.49
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 377.00
Adjustments for provisions, current 100.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (399.34)
Adjustments for dividend income 247.86
Adjustments for interest income 91.82
Adjustments for share-based payments 160.42
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (12,848.93)
Net cash flows from (used in) operations 5,700.56
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,708.28
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,992.28
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 12,319.55
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 1,962.33
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties (821.44)
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 247.86
Interest received 91.82
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (13,120.76)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1.10
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 16,289.55
Repayments of borrowings 1,205.55
Payments of lease liabilities 1,070.00
Dividends paid 1,813.60
Interest paid 2,510.89
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 9,690.61
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (437.87)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (437.87)
Cash and cash equivalents cash flow statement at beginning of period 553.67
Cash and cash equivalents cash flow statement at end of period 115.80





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Aarti Pharmalabs Limited Chandrakant V Gogri Promoter Any other transaction Rent 20.00 Approved 6.35 (0.90) (0.97)
2 Aarti Pharmalabs Limited Aarti Industries Limited Enterprise over which key managerial personnel are able to exercise significant influence Purchase of goods or services 5,000.00 Approved 3,032.31 (1,154.00) 0.00
3 Aarti Pharmalabs Limited Aarti Industries Limited Enterprise over which key managerial personnel are able to exercise significant influence Purchase of fixed assets 500.00 Approved 0.00 0.00 0.00
4 Aarti Pharmalabs Limited Aarti Industries Limited Enterprise over which key managerial personnel are able to exercise significant influence Sale of goods or services 10,000.00 Approved 5,289.84 919.80 11.57
5 Aarti Pharmalabs Limited Aarti Industries Limited Enterprise over which key managerial personnel are able to exercise significant influence Sale of fixed assets 500.00 Approved 0.00 0.00 0.00
6 Aarti Pharmalabs Limited Aarti Drugs Limited Enterprise over which key managerial personnel are able to exercise significant influence Purchase of goods or services 7,500.00 Approved 1,175.07 (336.57) (568.69)
7 Aarti Pharmalabs Limited Aarti Drugs Limited Enterprise over which key managerial personnel are able to exercise significant influence Sale of goods or services 2,000.00 Approved 1,245.06 152.04 0.00
8 Aarti Pharmalabs Limited Alchemie Gases and Chemicals Private Limited Private company in which Director's relative is member Purchase of goods or services 20.00 Approved 0.22 0.44 0.47
9 Aarti Pharmalabs Limited Valiant Organics Limited Promoter Group Purchase of goods or services 1,000.00 Approved 57.67 (995.84) (149.88)
10 Aarti Pharmalabs Limited Valiant Organics Limited Promoter Group Sale of goods or services 500.00 Approved 0.72 944.68 0.00
11 Aarti Pharmalabs Limited Valiant Organics Limited. Promoter Group Any other transaction Conducting cum Loan & License Fees 1,800.00 Approved 1,770.00 0.00 0.00
12 Aarti Pharmalabs Limited Valiant Organics Limited' Promoter Group Any other transaction Reimbursement of Expense 2,500.00 Approved 913.24 0.00 0.00
13 Aarti Pharmalabs Limited Valiant Organics Limited Promoter Group Interest received 150.00 Approved 60.16 0.00 0.00
14 Aarti Pharmalabs Limited Aarti USA Inc Wholly Owned Subsidiary Sale of goods or services 6,000.00 Approved 790.40 690.21 1,213.53
15 Aarti Pharmalabs Limited Aarti USA Inc Wholly Owned Subsidiary Purchase of goods or services 1,000.00 Approved 54.24 0.00 0.00
16 Aarti Pharmalabs Limited Ganesh Polychem Limited JV Sale of goods or services 2,500.00 Approved 1,800.41 770.05 599.28
17 Aarti Pharmalabs Limited Ganesh Polychem Limited JV Purchase of goods or services 2,500.00 Approved 137.96 (156.41) 0.00
18 Aarti Pharmalabs Limited Ganesh Polychem Limited' JV Any other transaction Sale of Service/ Job Work Charges 3,000.00 Approved 225.49 0.00 0.00
19 Aarti Pharmalabs Limited Ganesh Polychem Limited JV Interest paid 135.00 Approved 54.35 0.00 0.00
20 Aarti Pharmalabs Limited Valiant Laboratories Limited Enterprise over which key managerial personnel are able to exercise significant influence Sale of goods or services 1,000.00 Approved 181.05 31.14 20.01
21 Aarti Pharmalabs Limited Valiant Laboratories Limited Enterprise over which key managerial personnel are able to exercise significant influence Purchase of goods or services 1,000.00 Approved 317.93 (356.14) 0.00
22 Aarti Pharmalabs Limited Valiant Laboratories Limited. Enterprise over which key managerial personnel are able to exercise significant influence Any other transaction Rent 1,000.00 Approved 147.50 0.00 0.00
23 Aarti Pharmalabs Limited Alchemie Finechem Limited Other Related Party Sale of goods or services 5,000.00 Approved 430.93 4.09 387.75
24 Aarti Pharmalabs Limited Alchemie Finechem Limited Other Related Party Purchase of goods or services 500.00 Approved 0.00 (61.30) 0.00
25 Aarti Pharmalabs Limited Pinnacle Lifesciences Private Limited Other Related Party Sale of goods or services 3,000.00 Approved 411.54 239.95 381.22
26 Aarti Pharmalabs Limited Pinnacle Lifesciences Private Limited Other Related Party Purchase of goods or services 250.00 Approved 0.00 0.00 0.00
27 Aarti Pharmalabs Limited Anvi Speciality Chemicals Firm in which Director's Relative is Partner Sale of goods or services 300.00 Approved 0.00 0.00 0.00
28 Aarti Pharmalabs Limited Anvi Speciality Chemicals Firm in which Director's Relative is Partner Purchase of goods or services 750.00 Approved 129.65 (46.52) (41.46)
29 Aarti Pharmalabs Limited Amulya Techline Engineers (Div of Dilesh Roadlines Private Limited) Promoter Group Purchase of goods or services 3,000.00 Approved 252.66 9.02 (124.12)
30 Aarti Pharmalabs Limited Amulya Techline Engineers (Div of Dilesh Roadlines Private Limited) Promoter Group Sale of fixed assets 100.00 Approved 0.00 0.00 0.00
31 Aarti Pharmalabs Limited Aarti Ventures Private Limited Private Company in which Director is Member Interest received 55.00 Approved 26.34 189.67 0.00 Advance 9.00 On Demand Unsecured ICD
32 Aarti Pharmalabs Limited Kalpesh Roadlines Limited Controlling individuals / KMPs of the Company along with their relatives have significant influence Purchase of goods or services 1,500.00 Approved 591.08 (144.88) (263.26)
33 Aarti Pharmalabs Limited Aarti Surfactants Limited Any body corporate in which twenty per cent. or more of the equity share capital is held by the Individual Promoter or an immediate relative of the Individual Promoter or a firm or Hindu Undivided Family in which the Individual Promoter or any one or more of their relative is a member Sale of goods or services 100.00 Approved 7.27 0.00 6.84
34 Aarti Pharmalabs Limited Valiant Advanced Science Pvt Ltd Enterprise over which key managerial personnel are able to exercise significant influence Purchase of goods or services 10,000.00 Approved 2,176.29 (21.58) (554.86)
35 Aarti Pharmalabs Limited Valiant Advanced Science Pvt Ltd Enterprise over which key managerial personnel are able to exercise significant influence Sale of goods or services 5,000.00 Approved 549.12 0.00 0.00
36 Aarti Pharmalabs Limited Bio Fuel Circle Private Limited Enterprise over which director are able to exercise significant influence Purchase of goods or services 500.00 Approved 42.39 (7.48) (11.29)
37 Aarti Pharmalabs Limited Aarti Packwell Any body corporate in which a body corporate [in which Individual Promoter has prescribed holding] holds twenty per cent. or more, of the equity share capital Purchase of goods or services 500.00 Approved 0.00 0.00 0.00
38 Aarti Pharmalabs Limited Dhan Vallabh Welfare Foundation Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction CSR Expenditure 100.00 Approved 0.00 0.00 0.00
39 Aarti Pharmalabs Limited Dhanvallabh Charitable Trust Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction CSR Expenditure 100.00 Approved 0.00 0.00 0.00
40 Aarti Pharmalabs Limited Aarti Foundation Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction CSR Expenditure 700.00 Approved 210.00 0.00 0.00
41 Aarti USA Inc Aarti Industries Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Purchase of goods or services 2,000.00 Approved 0.00 0.00 0.00
42 Aarti USA Inc Aarti Surfactants Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Purchase of goods or services 1,000.00 Approved 0.00 0.00 0.00
43 Aarti Pharmalabs Limited Shri Rashesh C. Gogri Chairman Non Executive Non Independent Director Related to promoter Remuneration Approved 0.80 0.00 0.00
44 Aarti Pharmalabs Limited Shri Parimal Desai Non Executive Non Independent Director Related to Promoter Remuneration Approved 0.00 0.00 0.00
45 Aarti Pharmalabs Limited Smt. Nehal Garewal Non Executive Non Independent Director Related to Promoter Remuneration Approved 0.60 0.00 0.00
46 Aarti Pharmalabs Limited Shri Rajendra V. Gogri Non Executive Non Independent Director Related to Promoter Remuneration Approved 0.70 0.00 0.00
47 Aarti Pharmalabs Limited Smt. Hetal Gogri Gala Vice-Chairperson and Managing Director Remuneration Approved 712.27 0.00 0.00
48 Aarti Pharmalabs Limited Shri Narendra Salvi Managing Director Remuneration Approved 104.07 0.00 0.00
Total value of transaction during the reporting period 22,905.68